相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
Benjamin Kearns et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review
Mark Sinyor et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
Bertalan Nemeth et al.
HEALTH POLICY AND TECHNOLOGY (2019)
Effects of antidepressant and antipsychotic use on weight gain: A systematic review
Lucia Alonso-Pedrero et al.
OBESITY REVIEWS (2019)
Measuring costs of community mental health care in Italy: A prevalence-based study
F. Senese et al.
EUROPEAN PSYCHIATRY (2018)
Value of schizophrenia treatment II: Decision modelling for developing early detection and early intervention services in the Czech Republic
Petr Winkler et al.
EUROPEAN PSYCHIATRY (2018)
The economic burden of inpatient care of depression in Poznan (Poland) and Kiel (Germany) in 2016
Tomasz Zaprutko et al.
PLOS ONE (2018)
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis
Andrea Marcellusi et al.
BMJ OPEN (2018)
Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter!
Michael P. Hengartner et al.
FRONTIERS IN PSYCHIATRY (2018)
Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
A. H. Young et al.
JOURNAL OF AFFECTIVE DISORDERS (2017)
Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
Spyros Kolovos et al.
PHARMACOECONOMICS-OPEN (2017)
The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence
James Lomas et al.
PHARMACOECONOMICS (2016)
The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
Andre F. Carvalho et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2016)
Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review
Su Golder et al.
PLOS MEDICINE (2016)
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal
Thomas R. Einarson et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial
Habibolah Khazaie et al.
GENERAL HOSPITAL PSYCHIATRY (2015)
De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder
Lenka Pribylova et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2015)
Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study
Luca Degli Esposti et al.
BMC PSYCHIATRY (2014)
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis
Ursula Reichenpfader et al.
DRUG SAFETY (2014)
The deviance information criterion: 12 years on
David J. Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2014)
Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
Nikos Maniadakis et al.
BMC HEALTH SERVICES RESEARCH (2013)
Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study
Paolo A. Cortesi et al.
BMC PSYCHIATRY (2013)
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic
Thomas R. Einarson et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting
Mark J. C. Nuijten et al.
CLINICAL THERAPEUTICS (2012)
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Andrea Fagiolini et al.
CNS DRUGS (2012)
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Thomas R. Einarson et al.
ANNALS OF GENERAL PSYCHIATRY (2012)
A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS
John W. Stevens
PHARMACEUTICAL STATISTICS (2011)
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
Giorgio Colombo
Neuropsychiatric Disease and Treatment (2011)
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Alessandro Serretti et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden
Göran Nordström et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
Treatment-Emergent Sexual Dysfunction Related to Antidepressants A Meta-Analysis
Alessandro Serretti et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
Maria Geitona et al.
Annals of General Psychiatry (2008)
Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise
B. M. S. Heeg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions
PW Sullivan et al.
CNS DRUGS (2004)
Service utilisation and costs of first-contact patients in a community psychiatric service in Italy
M Percudani et al.
EUROPEAN PSYCHIATRY (2002)
Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic
L Hosák et al.
EUROPEAN PSYCHIATRY (2002)
Direct costs of schizophrenia in Italian community psychiatric services
L Garattini et al.
PHARMACOECONOMICS (2001)
分享论文
